FIELD: chemistry.
SUBSTANCE: claimed is a pharmaceutical composition, which contains as minimum one active component - a pharmaceutically acceptable salt of 6-[(4-methyl-1-1-piperazinyl)methyl]-indolo[1',7':1,2,3]pyrrolo[3',4':6,7]azepino[4,5-b]indole-1,3(2H,10 H)-dione of formula (I), in particular mesylate of 6-[(4-methyl-1-1-piperazinyl)methyl]-indolo[1',7':1,2,3]pyrrolo[3',4':6,7]azepino[4,5-b]indole-1,3(2H,10 H)-dione of formula (1) and as minimum one auxiliary substance.
EFFECT: demonstrated suppression of growth of adenocarcinoma and melanoma tumour.
2 tbl
Title | Year | Author | Number |
---|---|---|---|
PIM1-KINASE INHIBITOR 6-[(4-METHYL-I-1-PIPERAZINYL)METHYL]-INDOLO[1',7':1,2,3]PYRROLO[3',4':6,7]AZEPINO[4,5-b]INDOLE-1,3(2H, 10H)-DIONE, METHOD FOR PREPARING AND USING IT | 2011 |
|
RU2466132C1 |
PHARMACEUTICAL COMPOSITION BASED ON TRIINDOLYLMETHANE DERIVATIVE AS ANTI-TUMOUR MEDICATION | 2012 |
|
RU2549430C2 |
METHOD OF SYNTHESIS OF INDOLO[1',7':1,2,3]PIRROLO[3',4':6,7]AZEPINO[4,5-B]INDOL-1,3(2H,10H)-DIONE | 2017 |
|
RU2648039C1 |
ANTITUMOUR ANTHRAFURANDIONE AND BASED PHARMACEUTICAL COMPOSITIONS | 2014 |
|
RU2554939C1 |
4-(1-(4-(4-METHOXYPHENYLTHIO)-2,5-DIOXO-2,5-DIHYDRO-1H-PYRRO-3-YL)-1H-INDOL-3-YL)BUTYLCARBAMIMIDOTHIOATE AND METHOD FOR USING IT | 2009 |
|
RU2441000C2 |
NEW COMBINATION OF 3-[(3-{[4-(4-MORPHOLINYLMETHYL)-1N-PYRROL-2-YL]METHYLENE}-2-OXO-2,3-DIHYDRO-1N-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE AND TYROSINE KINASE INHIBITOR EGFR | 2016 |
|
RU2695362C2 |
MEDICINAL AGENT BASED ON 4-SUBSTITUTED 3(3-DIALKYLAMINOMETHYL-INDOL-1-YL)MALEIMIDE DERIVATIVES | 2006 |
|
RU2388759C2 |
DERIVATIVES OF GLYCOSIDES OF INDOLO[2,3-A]-PYRROLO[3,4-C]CARBAZOL-5,7-DIONES ELICITING CYTOTOXIC AND ANTITUMOR ACTIVITY | 2003 |
|
RU2255089C1 |
N-GLYCOSIDES OF INDOLO[2,3-a]PYRROLO[3,4-c]CARBAZOLES HAVING ANTITUMOUR ACTIVITY | 2014 |
|
RU2548045C1 |
SUBSTITUTED N-{3-[4-(1-METHYL-1H-INDOL-3-YL)PYRIMIDIN-2-YLAMINO]-4-METHOXYPHENYL}-AMIDES AS MODULATORS OF EGFR, APPLICABLE FOR TREATING CANCER | 2015 |
|
RU2606949C9 |
Authors
Dates
2014-07-20—Published
2013-03-19—Filed